Overview

Docetaxel and S-1 Combination Therapy as Second-line Treatment for Advanced Gastric Cancer

Status:
Unknown status
Trial end date:
2018-10-10
Target enrollment:
Participant gender:
Summary
A single-arm phase II study to evaluate the efficacy and safety of docetaxel plus S-1 (DS) as second-line treatment in patients with AGC.
Phase:
Phase 2
Details
Lead Sponsor:
Fujian Cancer Hospital
Treatments:
Docetaxel